Monobactams as enzyme inhibitors

IDrugs

Volumn 3, Issue 5, 2000, Pages 512-517

  Singh, Rajeshwar ^a   Micetich, Ronald G ^a  

^a NAEJA Pharmaceutical Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001651114     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Demuth HU: Recent developments in inhibiting cysteine and serine proteases. J Enzyme Inhib (1990) 3:249-278.
2. Babine RE, Bender SL: Molecular recognition of protein-ligand complexes: Application to drug design. Chem Rev (1997) 97:1359-1472.
3. Baggio R, Shi YQ, Wu Y, Abels RH: New concept in biochemistry-from poor substrate to good inhibitors: Design of inhibitors for serine and thiol proteases. Biochemistry (1996) 35:3351-3353.
4. Beauve C, Bouchet M, Touillaux R, Fastrez J, Marchand-Brynaert J: Synthesis, reactivity and biochemical evaluation of 1,3-substituted azetidin-2-ones as enzyme inhibitors. Tetrahedron (1999) 55:13301-13320.
5. Maiti SN, Phillips OA, Micetich RG, Livermore DM: β-lactamase inhibitors: Agents to overcome bacterial resistance. Curr Med Chem (1998) 5:441-456.
6. Ghuysen JM: Evolution of DD-peptidases and β-lactamase. In: Antibiotic inhibition of bacterial cell surface assembly and function, Actor P, Daneo-Moore L, Higgins ML, Salton MRJ, Shockmon GD (Eds), American Society of Microbiology, Washington, DC, USA, (1988) 268-284.
7. Rolinson GN: Evolution of β-lactamase inhibitors. Rev Infect Dis (1991) 13 (Suppl 9):S727-732.
8. Maiti SN, Phillips OA: β-lactamase inhibitors and β-lactam antibiotics: patent highlights June 1998 to November 1998. Curr Opin Anti-Infective Invest Drugs (1999) 1:40-44.
9. Maiti SN, Phillips OA, Setti EL, Reddy AVN, Goyal J, Czajkowski DP, Luu HT, Micetich RG, Singh R, Catena R: SYN-2190: synthesis and structure-activity relationships of a novel series of 2-oxo-1-azetidine sulfonic acids as potent β-lactamase inhibitors. ICAAC (1997) 37 Toronto F188.
10. Nishida K, Kunugita C, Uji T, Higashitani F, Hyodo A, Unemi N, Maiti SN, Phillips OA, Spevak P, Atchison KP, Salama SM, Atwal H, Micetich RG: In vitro and in vivo activities of SYN-2190, a novel β-lactamase inhibitor. Antimicrob Agents Chemother (1999) 43:1895-1900.
11. Atchison KP, Catena R, Kaleta J, Atwal H, Maiti SN, Micetich RG: SYN-2190: a novel potent β-lactamase inhibitor: kinetics of enzyme inhibition and penetration of the Pseudomonas aeruginosa outer membrane. ICAAC (1997) 37 Toronto F189.
12. Kunugita C, Nishida K, Uji T, Salama SM, Atwal H, Maiti SN, Micetich RG, Unemi N: SYN-2190: a novel potent β-lactamase inhibitor: in vitro activity in combination with ceftazidime, cefozopran, cefepime and cefpirome against β-lactamase producing strains and ceftazidime-resistant clinical isolates. ICAAC (1997) 37 Toronto F190.
13. Nishida K, Nishiyama T, Urata K, Hirakawa Y, Komuro M, Higashitani F, Khan JK, Maiti SN, Micetich RG, Unemi N: SYN-2190: a novel potent β-lactamase inhibitor: in vivo activity in combination with cephalosporins against class C β-lactamase producing strains. ICAAC (1997) 37 Toronto F192.
14. Hlasta DJ and Pagani EJ: Human leukocyte elastase inhibitors. In: Annual Report in Medicinal Chemistry. Bristol JA (Ed), Academic Press, New York (1994) 195-204.
15. Mascaretti OA, Boschetti CE, Danelon GO, Mata EG, Roveri OA: β-lactam compounds: inhibitors of transpeptidases, β-lactmases and elastases: A review. Curr Med Chem (1995) 1:441-470.
16. Maiti SN, Woods DE and Cantin AM: 2-Spirocyclopropyl cephem sulfones: human neutrophil elastase inhibitors Syn-1390 and Syn-1396. Drugs Future (1998) 23:635-641.
17. Finke PE, Shah SK, Reicher DS, Ashe BM, Brause KA, Chandler GO, Dellea PS, Hand KM, Maycock AL, Osinga DG, Underwood DJ, Weston H, Davies P, Doherty JB: Orally active β-lactam inhibitors of human leukocyte elastase. Stereospecific synthesis and structure-activity relationship for 3,3-dialkylazetidin-2-ones. J Med Chem (1995) 38:2449-2462.
18. Cvetovich RJ, Chartrain M, Harter Jr FW, Roberge C, Arnato JS, Grabowski EJJ: An asymétrie synthesis of L-694,458, a human leukocyte elastase inhibitor, via novel enzyme resolution of β-lactam esters. J Org Chem (1996) 61:6575-6580.
19. Chabin R, Green BG, Gate P, Maycock AL, Weston H, Dorn CP, Finke PE, Hagmann WK, Hale JJ, MacCoss M, Shah SK, Doherty JB, Knight WB: Mechanism of inhibition of human leukocyte elastase by monocyclic β-lactam. Biochemistry (1993) 32:8970-8980.
20. Green BG, Chabin R, Mills S, Underwood DJ, Shah SK, Kuo D, Gale P, Maycock AL, Liesch J, Burgey CS, Doherty JB, Dorn CP, Finke PE, Hagmann WK, Hale JJ, MacCoss M, Westler WM, Knight WB: Mechanism of inhibition of human leukocyte elastase by β-lactam. stability, reactivation kinetics, and products of β-lactam derived E-I complexes. Biochemistry (1995) 34:14331-14343.
21. Finke PE, Dorn CP, Kissinger AL, Shah SK, Ball RG, Chabin R, Davies P, Dellea PS, Doherty JB, Durette PL et al: Orally active intracellular inhibitor of human leukocyte elastase (HLE). ACS (1995) 22 Chicago MEDI 083.
22. Vincent SH, Painter SK, Luffer-Atlas D, Karanam BV, McGowan E, Cioffe C, Doss G, Chiu S-HL: Orally active inhibitors of human leukocyte elastase II. Identification of L-694,458 in rats and rhesus monkeys. Drug Metab Dispos (1997) 25:932-939.
23. Hilpert K, Ackermann J, Banner DW, Gast A, Gubemator K, Hadvary P, Labler L, Muller K, Schmid G, Tschopp TB, Waterbeemd H: Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem (1994) 37:3889-3901.
24. Han WT, Trehan AK, Wright JJ, Federici ME, Seiler SM, Meanwell NA: Azetidin-2-one derivatives as inhibitors of thrombin. Bioorg Med Chem (1995) 3:1123-1143.
25. Gibson W, Welch AR, Hall MRT: Assemblin, a herpes virus serine maturational proteinases and new molecular target for antiviral. Perspec Drug Disc Des (1994) 2:413-426.
26. Holwerda, BC: Herpevirus proteases: targets for novel drugs. Antiviral Res (1997) 35:1-21.
27. 0 with monocyclic β-lactams. Bioorg Med Chem Lett (1998) 8:1437-1442.
28. Yoakim C, Ogilvie WW, Cameron DR, Chabot C, Guse I, Hache B, Naud J, O'Meara JA, Plante R, Deziel R: β-lactams derivatives as inhibitors of human cytomegalovirus protease. J Med Chem (1998) 41:2882-2891.
29. Yoakim C, Ogilvie WW, Cameron DR, Chabot C, Grand-Maitre C, Guse I, Hache B, Kawai S, Naud J, O'Meara JA, Plante R, Deziel R: Potent β-lactam inhibitors of human cytomegalovirus protease. Antiviral Chem Chemother (1998) 9:379-387.
30. Milchaud S, Gour BJ: Cathepsin B inhibitors as potential antimetastatic agents. Exp Opin Ther Pat (1998) 8:645-672.
31. Smith WW, Abdel-Meguid SS: Cathepsin K as target for the treatment of osteoporosis. Exp Opin Ther Pat (1999) 9:683-694.
32. McGrath ME, Palmer JT, Brömme D, Somoza JR: Crystal Structures of human cathepsin S. Protein Sci (1998) 7:1294-1302.
33. Prestigiacomo AF, Stamey TA: A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. J Urol (1994) 152:1515-1519.
34. Klee GG, Preissner CM, Oesterling JE: Development of highly selective immunochemiluminometric assay for prostate-specific antigen. Urology (1994) 44:76-82.
35. Cohen P, Peehl DM, Graves HCB, Rosenfield RG: Biological effects of prostate specific antigen as an insulin like growth factor binding protein-3 protease. J Endocrinol (1994) 142:407-415.
36. Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH: Purification, properties, sequencing and cloning of a lipoprotein-associated, serine dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vase Biol (1996) 16:591-599.
37. Liu SY, Lu X, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, Choy PC, Man RYK: Alteration of lysophosphosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res (1994) 28:1476-1481.
38. 2 by monocyclic β-lactam: Burst kinetics and effect of stereochemistry. Biochemistry (1998) 37:10087-10093.
39. SYNPHAR LABORATORIES INC; TAIHO PHARMACEUTICAL CO LTD (Maiti SN, Setti EL, Phillips OA, Reddy AVN, Micetich RG, Singh R, Higashitani F, Kunugita C, Nishida K, Uji T): 2-Oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors. WO-09847895 (1998).
40. SYNPHAR LABORATORIES INC (Singh R, Zhou NE, Guo D, Micetich RG): 4-Substituted-3-peptidyl-azetidin-2-one derivatives useful as cysteine proteinase inhibitor. WO-09632408 (1996).
41. SYNPHAR LABORATORIES INC (Singh R, Zhou NE, Guo D, Micetich RG): 3,4-Disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators. WO-09812176 (1998), US-05959123 (1999).
42. SYNPHAR LABORATORIES INC; NATIONAL RESEARCH COUNCIL (Singh R, Zhou NE, Purishima EO, Micetich RG): 4-Substituted-3-(2-amino-2-cycloalkylmethyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators. WO-09812210 (1998), US-05916887 (1999).
43. SYNPHAR LABORATORIES INC (Singh R, Zhou NE, Reddy AVN, Micetich RG): Monobactam derivatives as cathepsin B, L, K and S inhibitors. WO-09948911 (1999).
44. ELI LILLY & CO LTD (Anderson BA, Becker GW, Carty JA, Ham NK, Hatfield LD, Neubauer BL, Rizzo JR, Zhang TY): Inhibitor of enzymatic activity of PSA. WO-09825895 (1998).
45. SMITHKLINE BEECHAM PLC (Mickey DMB, Dhanak D, Leach CA, Ife RJ, Tew DG): Azetidinone derivatives for the treatment of antherosclerosis. WO-09613484 (1996).
46. SMITHKLINE BEECHAM PLC (Hickey DMB, Dhanak D, Leach CA, Ife RJ, Tew DG): Substituted azetidin-2-ones for the treatment of atherosclerosis. WO-0961945 (1996).
47. SMITHKLINE BEECHAM PLC (Hickey DMB, Dhanak D, Ife RJ, Leach CA, Tew DG): Monocyclic β-lactam derivatives for the treatment of atherosclerosis. WO-09721675 (1997).
48. SMITHKLINE BEECHAM PLC (Hickey DMB, Dhanak D, Ife RJ, Leach CA, Tew DG): Azetidinone compounds for the treatment of atherosclerosis. WO-09721676 (1997).